Skip Navigation

JNCI Journal of the National Cancer Institute 2001 93(10):733; doi:10.1093/jnci/93.10.733
© 2001 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Cuzick, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cuzick, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 93, No. 10, 733, May 16, 2001
© 2001 Oxford University Press

EDITORIAL

Is Hormone Replacement Therapy Safe for Breast Cancer Patients?

Jack Cuzick

Correspondence to: Jack Cuzick, Ph.D., Imperial Cancer Research Fund, 61 Lincoln's Inn Fields, London WC2A 3PX, U.K. (e-mail: cuzick@icrf.icnet.uk).

The fundamental role of estrogens in the development of breast cancer is now well recognized. This role can be seen most clearly in the postmenopausal age range, where several studies have found that serum levels of endogenous estradiol are higher in women who develop breast cancer [reviewed in (1)]. Also, obesity, which is associated with increased postmenopausal estrogen production, is a clearly established risk factor for postmenopausal breast cancer. Likewise, the continuance of premenopausal status is a strong risk factor for breast cancer, and the risk is increased by about 2.8% for each additional year . . . [Full Text of this Article]

REFERENCES


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?